15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Bio-Techne Corp, 3 rate it Buy or better, 10 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $50.00 to $79.00, a moderate spread. The average target of $68.55 sits 5% below the current $72.09. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.44 next quarter toward $2.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy323%
Hold1077%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Bio-Techne Corp.
As of Jul, 3 of 13 firms rate TECH a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TECH EPS & revenue forecast
EPS · NEXT QUARTER
$0.44
Range $0.42 – $0.47 · 8 analysts · +5% YoY
Next period, 8 analysts expect Bio-Techne Corp to earn $0.44 a share (range $0.42 – $0.47), versus $0.42 a year earlier. , growing to $2.05 the year after.
REVENUE · NEXT QUARTER
$291.4M
Range $287.1M – $294.6M · 8 analysts · +2% YoY
Revenue is expected to reach $291.4M (range $287.1M – $294.6M), +1.7% year-over-year., rising to $1.3B next year.
Top analysts covering Bio-Techne Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TECH.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #196
Buy
$75.00+4.0% to target
Overall win rate
45%
+ Follow
#2
David Westenberg
Piper Sandler · Rank #227
Hold
$65.00-9.8% to target
Overall win rate
31%
+ Follow
#3
RW
Robert Wasserman
Benchmark · Rank #259
Hold
No targeton TECH
Overall win rate
39%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #260
Hold
$73.00+1.3% to target
Overall win rate
32%
+ Follow
#5
Paul Knight
Keybanc · Rank #296
Hold
No targeton TECH
Overall win rate
32%
+ Follow
TECH stock forecast FAQ
What is TECH's average 12-month price target?+
The 11 analysts with a live target average $68.55 for Bio-Techne Corp over the next 12 months, ranging from a $79.00 high to a $50.00 low.
Is TECH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 3 are Buy or Strong Buy, 10 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TECH?+
The Street-high target is $79.00 (UBS), and the Street-low is $50.00 (Evercore ISI Group). The average of all 11 active targets is $68.55.
How many Wall Street analysts cover TECH?+
13 analysts have an active rating on Bio-Techne Corp, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering TECH?+
Among analysts who currently cover TECH, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #196). Their current call is Buy with a $75.00 target.
What is Bio-Techne Corp's projected EPS for next quarter?+
The consensus estimate is $0.44 per share (range $0.42 – $0.47) across 8 analysts, rising to $2.05 the following year.
How much revenue is Bio-Techne Corp expected to report next quarter?+
Consensus revenue is $291.4M (range $287.1M – $294.6M), growing to $1.3B next year.
Have analysts been upgrading or downgrading TECH lately?+
As of Jul, 3 of 13 firms rate TECH a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TECH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
